Outcome of Board Meeting scheduled to be held on 29th May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals Ltd held its Board Meeting on 29th May 2026 and approved the audited financial results for FY ended 31st March 2026. The company reported revenue from operations of Rs 2,303.97 Lakhs, down from Rs 2,561.02 Lakhs in the previous year. Net profit stood at Rs 386.52 Lakhs compared to Rs 428.77 Lakhs in FY 2025, representing a decline. Basic EPS dropped to Rs 4.54 from Rs 6.14 year-on-year. Total assets grew significantly to Rs 5,164.55 Lakhs from Rs 2,812.31 Lakhs, largely due to an IPO raising Rs 2,396.10 Lakhs. Trade receivables increased substantially to Rs 3,656.80 Lakhs from Rs 2,454.96 Lakhs. The company incurred heavy capital expenditure of Rs 1,006.26 Lakhs in property, plant and equipment. Operating cash flow was negative at Rs 1,017.95 Lakhs. Statutory auditors Panchal SK & Associates issued an unmodified opinion.
Revenue and profit declined year-on-year while the balance sheet grew significantly due to IPO proceeds. The rise in trade receivables and negative operating cash flow warrant monitoring. However, the clean audit opinion provides assurance on financial reporting quality.